TransCode Therapeutics Inc. Common Stock (NASDAQ:RNAZ) went down by -7.96% from its latest closing price compared to the recent 1-year high of $7.00. The company’s stock price has collected 5.41% of gains in the last five trading sessions. Press Release reported on 07/13/21 that TransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Over-allotment Option
Is It Worth Investing in TransCode Therapeutics Inc. Common Stock (NASDAQ :RNAZ) Right Now?
Opinions of the stock are interesting as 0 analysts out of 0 who provided ratings for TransCode Therapeutics Inc. Common Stock declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
RNAZ currently public float of 2.95M. Today, the average trading volume of RNAZ was 4.19M shares.
RNAZ’s Market Performance
The simple moving average for the period of the last 20 days is -19.30% for RNAZ stocks with a simple moving average of -19.30% for the last 200 days.
RNAZ Trading at -19.30% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.43% of loss for the given period.
During the last 5 trading sessions, RNAZ rose by +5.41%, in comparison to the 20-day moving average. In addition, TransCode Therapeutics Inc. Common Stock saw -41.02% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.05.